Search company, investor...
Excilone company logo

Excilone

excilone.com

Founded Year

2008

About Excilone

Excilone operates as a biotechnology solutions company. It specializes in imaging and nanogenomics. It also provides solutions for imaging and automation for the preparation of samples for cytogenetics. The company was founded in 2008 and is based in Elancourt, France.

Headquarters Location

6-10 Rue Blaise Pascal,

Elancourt, 78990,

France

Missing: Excilone's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Excilone's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Excilone Patents

Excilone has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/26/2017

5/11/2021

Molecular biology, Nanotechnology, Membrane biology, Biotechnology, Polymer chemistry

Grant

Application Date

6/26/2017

Grant Date

5/11/2021

Title

Related Topics

Molecular biology, Nanotechnology, Membrane biology, Biotechnology, Polymer chemistry

Status

Grant

Excilone Frequently Asked Questions (FAQ)

  • When was Excilone founded?

    Excilone was founded in 2008.

  • Where is Excilone's headquarters?

    Excilone's headquarters is located at 6-10 Rue Blaise Pascal,, Elancourt.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.